NVHR Statement on the Passage of the Opioid Crisis Response Act of 2018

 
 
Share this
 
 

 

National Viral Hepatitis Roundtable (NVHR) Statement on the Passage of the Opioid Crisis Response Act of 2018, Legislation to Address Opioid-Related Infectious Diseases

Washington, DC – (September 17, 2018) – National Viral Hepatitis Roundtable (NVHR) Interim Executive Director Tina Broder today released the following statement applauding the United States Senate for passing the Opioid Crisis Response Act of 2018:

The National Viral Hepatitis Roundtable (NVHR) applauds the Senate for passing S. 2680, the Opioid Crisis Response Act of 2018, which will help address the devastating effects of the opioid and viral hepatitis epidemics in the U.S. There is a direct link between injectable opioid use and viral hepatitis, and any initiative to tackle the opioid crisis in America must include a robust effort to screen, vaccinate and treat people for these deadly infectious diseases. At least 5 million individuals in the U.S. are living with hepatitis B or C, and as rates of opioid injection drug use have climbed, so too have hepatitis B and C diagnoses.

“S. 2680 will address underfunding in communities impacted by the opioid epidemic and will bolster the surveillance system to help better handle infection outbreaks and respond more effectively to drive down the rates of new infections. We urge the House-Senate Conference Committee to quickly reach a compromise and for President Trump to promptly sign the opioid legislation into law to help save countless lives, to ensure that more individuals receive curative treatments for hepatitis B and hepatitis C, and to help Americans impacted by the dual threat of opioid injection drug use and viral hepatitis.”